Jason Park, Ph.D. is an Operating Partner at Flagship Pioneering where he leads a team of entrepreneurial scientists to develop the science, intellectual property, and business strategy that form the foundation of Flagship’s next breakthrough companies. Jason is a co-founder and member of the founding teams of Empress Therapeutics, where he is currently President and CEO, and Sonata Therapeutics, where he also served as COO.
Prior to joining Flagship in 2015, Jason was a core member of the Boston Consulting Group’s Health Care and Technology practices, operating out of BCG's New York, Mumbai, and Paris offices. His projects included several large life science M&A opportunities, and the design and implementation of a new funding model for a multinational global health organization focused on investing in innovative technologies and interventions. Previously, Jason was a director at an early-stage biotech start-up focused on targeted drug delivery as well as the co-founder of an internet advertising firm.
Jason earned a Ph.D., M.S., and B.S. in Biomedical Engineering from Yale University where his research focused on the use of nanotechnology for immunomodulatory purposes and culminated in the invention and clinical use of a nanoparticle drug delivery platform. He is the author of multiple patents, book chapters, and over a dozen peer-reviewed papers in journals including Nature and Cell.